Combination therapy • Late-breaking abstract • Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD27 (CD27 Molecule) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression • CSF2 expression • CTLA4 expression • High inflammation signature scores
|
PD-L1 IHC 28-8 pharmDx
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • RP2 • vusolimogene oderparepvec (RP1)